Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification

Detalles Bibliográficos
Autores principales: Zhao, Zhi-Mei, Wang, Song-Ping, Sun, Lei, Ji, You-Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846480/
https://www.ncbi.nlm.nih.gov/pubmed/33186133
http://dx.doi.org/10.1097/CM9.0000000000001184
_version_ 1783644740363747328
author Zhao, Zhi-Mei
Wang, Song-Ping
Sun, Lei
Ji, You-Xin
author_facet Zhao, Zhi-Mei
Wang, Song-Ping
Sun, Lei
Ji, You-Xin
author_sort Zhao, Zhi-Mei
collection PubMed
description
format Online
Article
Text
id pubmed-7846480
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-78464802021-02-05 Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification Zhao, Zhi-Mei Wang, Song-Ping Sun, Lei Ji, You-Xin Chin Med J (Engl) Correspondence Lippincott Williams & Wilkins 2021-02-05 2020-11-12 /pmc/articles/PMC7846480/ /pubmed/33186133 http://dx.doi.org/10.1097/CM9.0000000000001184 Text en Copyright © 2021 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Correspondence
Zhao, Zhi-Mei
Wang, Song-Ping
Sun, Lei
Ji, You-Xin
Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification
title Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification
title_full Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification
title_fullStr Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification
title_full_unstemmed Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification
title_short Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification
title_sort crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired met amplification
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846480/
https://www.ncbi.nlm.nih.gov/pubmed/33186133
http://dx.doi.org/10.1097/CM9.0000000000001184
work_keys_str_mv AT zhaozhimei crizotinibpluserlotinibovercomesosimertinibresistanceinaseriouslyillnonsmallcelllungcancerpatientwithacquiredmetamplification
AT wangsongping crizotinibpluserlotinibovercomesosimertinibresistanceinaseriouslyillnonsmallcelllungcancerpatientwithacquiredmetamplification
AT sunlei crizotinibpluserlotinibovercomesosimertinibresistanceinaseriouslyillnonsmallcelllungcancerpatientwithacquiredmetamplification
AT jiyouxin crizotinibpluserlotinibovercomesosimertinibresistanceinaseriouslyillnonsmallcelllungcancerpatientwithacquiredmetamplification

Ejemplares similares